newsfilter
← Latest News
GlobeNewswire·

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature